SEC Comment Letter 0000000000-24-003187 to Haoxi Health Technology Ltd (HAO)

Haoxi Health Technology Ltd
Date: March 22, 2024 · CIK: 0001954594 · Accession: 0000000000-24-003187

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

March 22, 2024

Author

Zhen Fan

Form

UPLOAD

Company

Haoxi Health Technology Ltd

Letter

United States securities and exchange commission logo March 22, 2024 Zhen Fan Chief Executive Officer Haoxi Health Technology Ltd Room 801, Tower C, Floor 8 Building 103 Huizhongli, Chaoyang District Beijing, China Re:Haoxi Health Technology Ltd Draft Registration Statement on Form F-1 Submitted March 15, 2024 CIK No. 0001954594 Dear Zhen Fan: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Nicholas Nalbantian at 202-551-7470 with any questions. Sincerely, Division of Corporation Finance Office of Trade & Services cc: Ying Li

Show Raw Text

United States securities and exchange commission logo
March 22, 2024
Zhen Fan
Chief Executive Officer
Haoxi Health Technology Ltd
Room 801, Tower C, Floor 8
Building 103
Huizhongli, Chaoyang District
Beijing, China
Re:Haoxi Health Technology Ltd
Draft Registration Statement on Form F-1
Submitted March 15, 2024
CIK No. 0001954594
Dear Zhen Fan:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Nicholas Nalbantian at 202-551-7470 with any questions.
Sincerely,
Division of Corporation Finance
Office of Trade & Services
cc:       Ying Li

SecProbe.io